Merryn Voysey

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 160 publications

Seroefficacy of a 10-valent pneumococcal conjugate vaccine (Pneumosil®) compared with other pneumococcal conjugate vaccines in children.

Seroefficacy of a 10-valent pneumococcal conjugate vaccine (Pneumosil®) compared with other pneumococcal conjugate vaccines in children.

Journal: Vaccine

Published: June 12, 2026

Correction: Leveraging paired serology to estimate the incidence of typhoidal Salmonella infection in the STRATAA study.

Correction: Leveraging paired serology to estimate the incidence of typhoidal Salmonella infection in the STRATAA study.

Journal: PLoS neglected tropical diseases

Published: April 15, 2026

Measles in Ugandan Children Under 18 Months of Age: A Retrospective Study of Case-based Surveillance, 2018-2024.

Measles in Ugandan Children Under 18 Months of Age: A Retrospective Study of Case-based Surveillance, 2018-2024.

Journal: Open forum infectious diseases

Published: April 14, 2026

Predicting Salmonella Typhi incidence using prevalence metrics from sentinel studies of community-onset bloodstream infections: a secondary analysis of observational data.

Predicting Salmonella Typhi incidence using prevalence metrics from sentinel studies of community-onset bloodstream infections: a secondary analysis of observational data.

Journal: Vaccine

Published: March 23, 2026

Baseline adverse birth outcomes in a prospective pregnancy cohort in Uganda: Evidence to inform maternal vaccine readiness.

Baseline adverse birth outcomes in a prospective pregnancy cohort in Uganda: Evidence to inform maternal vaccine readiness.

Journal: Vaccine

Published: March 23, 2026

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.

Journal: Vaccine

Published: March 19, 2026

Safety and immunogenicity of GBS6 in pregnant women living with and without HIV and their infants in Uganda (PREPARE WP4): a double-blind, randomised, placebo-controlled, phase 2 clinical trial.

Safety and immunogenicity of GBS6 in pregnant women living with and without HIV and their infants in Uganda (PREPARE WP4): a double-blind, randomised, placebo-controlled, phase 2 clinical trial.

Journal: The Lancet. Infectious diseases

Published: March 06, 2026

8-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in children in Nepal (TyVOID): a prospective cohort follow-up study of the TyVAC Nepal randomised controlled trial.

8-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in children in Nepal (TyVOID): a prospective cohort follow-up study of the TyVAC Nepal randomised controlled trial.

Journal: The Lancet. Global health

Published: March 05, 2026

Preliminary safety data from a randomised trial of early versus standard timing of administration of measles-rubella vaccine in Ugandan infants.

Preliminary safety data from a randomised trial of early versus standard timing of administration of measles-rubella vaccine in Ugandan infants.

Journal: Discover medicine

Published: November 22, 2025

Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.

Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.

Journal: The Lancet. Infectious diseases

Published: November 11, 2025

A statistical method for evaluating vaccine-induced immune correlates of protection against infection and disease progression: application to the ChAdOx1-S nCoV-19 phase 3 trial.

A statistical method for evaluating vaccine-induced immune correlates of protection against infection and disease progression: application to the ChAdOx1-S nCoV-19 phase 3 trial.

Journal: Vaccine

Published: July 30, 2025

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.

Journal: Mayo Clinic proceedings. Innovations, quality & outcomes

Published: July 21, 2025

Showing 1-12 of 160

Last Updated: 09/26/2026